This company listing is no longer active
Albireo Pharma Past Earnings Performance
Past criteria checks 0/6
Key information
-18.06%
Earnings growth rate
-3.02%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 49.25% |
| Return on equity | -131.05% |
| Net Margin | -228.51% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Revenue & Expenses Breakdown
How Albireo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 57 | -131 | 80 | 87 |
| 30 Jun 22 | 51 | -36 | 77 | 85 |
| 31 Mar 22 | 45 | -33 | 72 | 83 |
| 31 Dec 21 | 41 | -34 | 71 | 81 |
| 30 Sep 21 | 11 | -48 | 65 | 81 |
| 30 Jun 21 | 9 | -136 | 59 | 82 |
| 31 Mar 21 | 9 | -120 | 51 | 79 |
| 31 Dec 20 | 8 | -108 | 44 | 76 |
| 30 Sep 20 | 12 | -90 | 35 | 70 |
| 30 Jun 20 | 11 | -82 | 30 | 60 |
| 31 Mar 20 | 11 | -78 | 27 | 53 |
| 31 Dec 19 | 10 | -63 | 24 | 45 |
| 30 Sep 19 | 4 | -71 | 23 | 41 |
| 30 Jun 19 | 3 | -63 | 21 | 38 |
| 31 Mar 19 | 2 | -61 | 20 | 34 |
| 31 Dec 18 | 13 | -46 | 18 | 31 |
| 30 Sep 18 | 12 | -35 | 17 | 26 |
| 30 Jun 18 | 12 | -28 | 17 | 19 |
| 31 Mar 18 | 11 | -19 | 17 | 16 |
| 31 Dec 17 | 0 | -24 | 16 | 13 |
| 30 Sep 17 | 3 | -31 | 16 | 10 |
| 30 Jun 17 | 3 | -28 | 13 | 9 |
| 31 Mar 17 | 11 | -20 | 12 | 9 |
| 31 Dec 16 | 11 | -16 | 10 | 8 |
| 30 Sep 16 | 13 | -5 | 8 | 8 |
| 30 Jun 16 | 13 | -4 | 8 | 7 |
| 31 Mar 16 | 5 | -8 | 5 | 6 |
Quality Earnings: ALBO is currently unprofitable.
Growing Profit Margin: ALBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Return on Equity
High ROE: ALBO has a negative Return on Equity (-131.05%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/03 08:48 |
| End of Day Share Price | 2023/03/02 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Albireo Pharma, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| null null | Guggenheim Securities, LLC |
| Seamus Fernandez | Guggenheim Securities, LLC |